News Sentiment

ONCY sentiment intelligence

Oncolytics Biotech Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.89 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -1.3% Price digesting
Trend fit Trend inactive 10.5% over four weeks
Fair value -19.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 45
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 10
GlobeNewswire 6
TradingView 6
simplywall.st 6
Moomoo 3
GuruFocus 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 11
Regulatory and legal 4
Analyst action 3
Guidance 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Moomoo Direct company coverage

Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer

Oncolytics Biotech's shares rose following news of their plans to meet with the FDA regarding a registrational study for their drug pelareorep in metastatic pancreatic cancer, and positive interim data from a Phase 1/2 colorectal cancer trial. The company's strategy involves the

Tone
Positive 72/100
Event
Market update
Published
13 Jul 2026 15:42
Source
Moomoo
Stock Titan Direct company coverage

Cancer trial using pelareorep seeks FDA input on path to possible approval

Oncolytics Biotech (ONCY) has reported significant clinical and regulatory progress for its REO 033 study, which evaluates pelareorep in patients with RAS-mutant MSS metastatic colorectal cancer. The company plans a Type D FDA meeting in early August 2026 to discuss adding a regi

Tone
Positive 75/100
Event
Regulatory and legal
Published
13 Jul 2026 12:42
Source
Stock Titan
GlobeNewswire Direct company coverage

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics Biotech is making strong clinical and regulatory progress with its REO 033 study for RAS-mutant, MSS metastatic colorectal cancer, with half of the planned clinical sites now activated and over 20 patients pre-identified. The company will hold a Type D meeting with the

Tone
Positive 71/100
Event
Regulatory and legal
Published
13 Jul 2026 12:40
Source
GlobeNewswire
Stock Titan Direct company coverage

Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor

Oncolytics Biotech Inc. (ONCY) announced the replacement of Ernst & Young LLP with Baker Tilly US, LLP as its independent registered public accounting firm for the 2026 fiscal year due to corporate restructuring. The company confirmed that there were no disagreements with EY, and

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 07:39
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Oncolytics Biotech Inc. – NASDAQ:ONCY

This article displays the "Enterprise value to EBITDA forward" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY) on TradingView. It provides a historical overview of this specific financial ratio for the company, accessible through the platform's financial data section. The conte

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 06:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Oncolytics Biotech Inc. – NASDAQ:ONCY

This article focuses on the enterprise value to revenue forward metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It extracts financial information related to the company from TradingView, specifically highlighting its presence on the Nasdaq Stock Market. The content primarily c

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 17:10
Source
TradingView
TradingView Direct company coverage

ONCY Forecast — Price Target — Prediction for 2027

This article provides a forecast for Oncolytics Biotech Inc. (ONCY) stock, including analyst price targets and historical performance. It details the company's current stock price, market capitalization, earnings, and revenue, alongside a disclaimer that the information is not in

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 14:09
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Oncolytics Biotech Inc. – NASDAQ:ONCY

This article displays the "Price to sales forward" metric for Oncolytics Biotech Inc. (NASDAQ: ONCY). It appears to be a financial data point presented on a trading platform, indicating the company's valuation based on its projected sales. The article is sparse, primarily showing

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:39
Source
TradingView
Moomoo Direct company coverage

Oncolytics Biotech | 8-K: Current report

This document is an 8-K filing by Oncolytics Biotech, a current report submitted to the Securities and Exchange Commission. The 8-K form is used by public companies to announce major events that shareholders should know about.

Tone
Neutral 50/100
Event
Market update
Published
21 Jun 2026 14:40
Source
Moomoo
Market source Direct company coverage

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech Inc. announced that the USPTO has issued a new patent protecting its proprietary manufacturing process for pelareorep until 2044, enabling commercial-scale production. The company also has a method-of-use patent application that could extend protection to 2046

Tone
Positive 74/100
Event
Market update
Published
19 Jun 2026 01:39
Source
Market source
TradingKey Direct company coverage

Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Oncolytics Biotech Inc (ONCY), focusing on its current valuation score, P/E ratio, and industry ranking. The company's valuation score is 7.92, placing it 187th out of 388 in the Biotechnology & Medical Research industry. It notes tha

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:10
Source
TradingKey
TradingKey Direct company coverage

Oncolytics Biotech Inc (ONCY) Institutional Confidence

This article analyzes the institutional confidence in Oncolytics Biotech Inc (ONCY), which currently holds a score of 3.00, placing it 193rd in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 80.02% quarter-over-quarter, r

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:10
Source
TradingKey
GuruFocus Direct company coverage

Oncolytics Biotech® to Host Conference Call to Discuss First Qua

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) announced it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET. The call will cover a corporate update and financial results for the first quarter of 2024. Oncolytics is a clinical-stage biotechnolo

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 03:10
Source
GuruFocus
Baystreet.ca Direct company coverage

Oncolytics Biotech Inc

Oncolytics Biotech Inc. announced that the United States Patent and Trademark Office has issued a new patent covering its proprietary manufacturing process for pelareorep. This patent broadly protects key aspects of their manufacturing methods and is expected to provide intellect

Tone
Positive 72/100
Event
Market update
Published
16 Jun 2026 13:41
Source
Baystreet.ca
TradingView Direct company coverage

Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process

Oncolytics Biotech has announced that it has been granted a new US patent for its pelareorep manufacturing process. The article, while brief, indicates that this is a significant development for the company.

Tone
Positive 72/100
Event
Market update
Published
16 Jun 2026 13:39
Source
TradingView
Stock Titan Direct company coverage

US patent shields Oncolytics' pelareorep manufacturing process into 2044

Oncolytics Biotech has secured a new U.S. patent that protects its proprietary manufacturing process for pelareorep, an investigational immunotherapy, until 2044. This patent aims to ensure consistent commercial-scale production and is a significant addition to the company's inte

Tone
Positive 73/100
Event
Regulatory and legal
Published
16 Jun 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044

Oncolytics Biotech Inc. announced a new U.S. patent that protects the commercial manufacturing process of its investigational immunotherapy, pelareorep, until 2044. The company also has a pending method-of-use patent application that, if granted, could extend protection to 2046,

Tone
Positive 72/100
Event
Regulatory and legal
Published
16 Jun 2026 12:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)

LifeSci Capital reiterated a Buy rating for Enliven Therapeutics (ELVN) with a $60.00 price target, highlighting the company's Strong Buy consensus among analysts. Conversely, JonesTrading maintained a Hold rating on Oncolytics Biotech (ONCY), despite a Strong Buy consensus and a

Tone
Positive 63/100
Event
Analyst action
Published
12 Jun 2026 19:08
Source
The Globe and Mail
Moomoo Direct company coverage

JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating

JonesTrading has reiterated its Hold rating on Oncolytics Biotech (ONCY.US). This action indicates that the firm is maintaining its current neutral stance on the company's stock.

Tone
Neutral 50/100
Event
Analyst action
Published
12 Jun 2026 02:40
Source
Moomoo
Stocktwits Direct company coverage

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study

Oncolytics Biotech (ONCY) shares surged over 12% following promising preclinical data for its immunotherapy, Pelareorep. The therapy, when combined with RAS-targeting drugs, showed stronger anti-tumor effects, leading Oncolytics to plan expanded testing in pancreatic and colorect

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 23:39
Source
Stocktwits
Finviz Direct company coverage

ONCY - Oncolytics Biotech Inc Stock Price and Quote

This page provides detailed financial information and recent news for Oncolytics Biotech Inc (ONCY). It covers stock performance, key financial metrics, insider transactions, and a chronological list of company announcements and analyst ratings. The data indicates ONCY is a biote

Tone
Positive 65/100
Event
Analyst action
Published
08 Jun 2026 07:10
Source
Finviz
ChartMill Direct company coverage

ONCY Stock Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY)

This page provides the stock chart and current price information for ONCOLYTICS BIOTECH INC (NASDAQ: ONCY). As of the close on June 8, 2026, the stock price was 0.84 USD. The page also features various trading tools and market data analysis options for users.

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 06:39
Source
ChartMill
Stock Titan Direct company coverage

Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options

Oncolytics Biotech (NASDAQ: ONCY) director Jonathan Rigby was granted 30,000 stock options with an exercise price of $1.06 per share, matching the June 1, 2026 closing price. The options vest in three equal annual installments, beginning June 1, 2027, and expire on June 1, 2036.

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 17:38
Source
Stock Titan
Stock Titan Direct company coverage

ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06

ONCOLYTICS BIOTECH INC director Wayne Pisano was granted 30,000 stock options at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options will vest in three equal annual installments, with the first vesting on June 1, 2027, provided Pisano r

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 17:38
Source
Stock Titan